Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q3 2021 vs. Q2 2021
How the institutions holding Genmab A/S changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 213 | 3 | 213 | +3 |
| Shares | 46.2M | 22.5K | 42.8M | −3.38M (−7.3%) |
| Value | $1.89B | $919.0K | $1.89B | +$3.57M (+0.2%) |
3 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (30)
Institutions that held Genmab A/S at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (27)
Institutions that held Genmab A/S at the end of Q2 2021 and filed for Q3 2021 without it.
Not filed for Q3 2021 yet (3)
Institutions that held Genmab A/S at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| CWM, LLC | 20,155 | $823.0K |
| First Horizon Corp | 1,323 | $54.0K |
| San Francisco Sentry Investment Group (Ca) | 1,018 | $42.0K |